Immunome (NASDAQ:IMNM) Director Sells $2,259,000.00 in Stock

Immunome, Inc. (NASDAQ:IMNM) Director Isaac Barchas sold 100,000 shares of the business’s stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $22.59, for a total transaction of $2,259,000.00. Following the completion of the sale, the director owned 208,504 shares in the company, valued at $4,710,105.36. This represents a 32.41% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Isaac Barchas also recently made the following trade(s):

• On Tuesday, June 30th, Isaac Barchas sold 101,050 shares of Immunome stock. The stock was sold at an average price of $21.12, for a total transaction of $2,134,176.00.

Immunome Price Performance

Shares of NASDAQ:IMNM traded up $2.12 during trading hours on Thursday, hitting $23.61. 1,869,014 shares of the company’s stock traded hands, compared to its average volume of 1,683,587. Immunome, Inc. has a 1 year low of $7.96 and a 1 year high of $27.65. The firm has a market capitalization of $2.67 billion, a P/E ratio of -9.92 and a beta of 2.07. The business has a fifty day moving average price of $20.96 and a 200-day moving average price of $21.78.

Immunome (NASDAQ:IMNM) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.48) EPS for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.12. As a group, equities analysts predict that Immunome, Inc. will post -2.06 earnings per share for the current year.

Institutional Trading of Immunome

Several institutional investors and hedge funds have recently bought and sold shares of IMNM. KBC Group NV purchased a new stake in shares of Immunome in the 1st quarter valued at approximately $60,000. BNP Paribas Financial Markets boosted its holdings in Immunome by 81.8% in the second quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company’s stock valued at $60,000 after purchasing an additional 2,909 shares in the last quarter. Strs Ohio acquired a new position in Immunome in the fourth quarter valued at approximately $64,000. Tower Research Capital LLC TRC raised its holdings in Immunome by 121.2% during the second quarter. Tower Research Capital LLC TRC now owns 6,938 shares of the company’s stock worth $65,000 after purchasing an additional 3,802 shares in the last quarter. Finally, Russell Investments Group Ltd. acquired a new stake in Immunome during the third quarter worth approximately $76,000. 44.58% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on IMNM. Wall Street Zen cut Immunome from a “hold” rating to a “sell” rating in a research report on Saturday, May 30th. Barclays began coverage on shares of Immunome in a research note on Thursday, May 28th. They set an “overweight” rating and a $36.00 price objective on the stock. Stephens cut their price objective on shares of Immunome from $33.00 to $30.00 and set an “overweight” rating for the company in a report on Wednesday, March 4th. Craig Hallum increased their target price on Immunome from $33.00 to $36.00 and gave the company a “buy” rating in a report on Wednesday, March 4th. Finally, HC Wainwright reiterated a “buy” rating and set a $40.00 price target on shares of Immunome in a research report on Wednesday, May 13th. Twelve analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Immunome presently has a consensus rating of “Moderate Buy” and a consensus target price of $33.17.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.